Clinical trials
CAR T Cell clinical trials
Below are recruiting car t cell clinical trials, each written for real people, not researchers. We’re tracking 697 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04892433Recruiting
Tissue study for people getting CAR-T cell therapy
This study looks at tissue samples from adults who are receiving CAR-T cell therapy for blood-related conditions. It aims to learn more about how CAR-T works and what changes happen in the body, which may help improve future care.
Bologna, ItalyAges 18–70 - NCT07227571RecruitingPhase 1
CAR T cells for advanced osteosarcoma
This trial tests whether specially engineered immune cells (called CAR T cells) can attack and kill osteosarcoma tumors that have not responded to standard treatments. It may be an option for children and adults whose cancer has returned or is not controlled by chemotherapy.
Seattle, WashingtonAges 1–75 - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT07695012RecruitingEarly Phase 1
CAR-T cell therapy for B-cell acute lymphoblastic leukemia
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
RawalpindiAges 5–50 - NCT06347068RecruitingPhase 1
CAR-T cell therapy for triple-negative breast cancer
This trial tests a new treatment using your own immune cells, modified to target a protein called B7-H3 on triple-negative breast cancer cells. It may help if other treatments haven't worked.
Chapel Hill, North CarolinaAges 18 years+ - NCT06652633RecruitingPhase 3
Long-term follow-up of Galapagos CAR T-cell therapy recipients
This study is for people who have already received a specific type of cell therapy (CAR T-cell therapy) made by Galapagos. It will follow them over the long term to see how they are doing.
Boston, MassachusettsAges 18 years+ - NCT05990465RecruitingPhase 1
LV20.19 CAR T-cells plus pirtobrutinib for relapsed B-cell lymphoma
This trial combines a new type of CAR T-cell therapy (LV20.19) with a targeted pill called pirtobrutinib to treat B-cell lymphomas that have come back or stopped responding. The goal is to see if this combination works better than each alone.
Milwaukee, WisconsinAges 18–81 - NCT06635330RecruitingPhase 1/Phase 2
CAR T cell therapy for children with relapsed B-cell leukemia
This trial tests a new CAR T cell treatment for children whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The goal is to see if this therapy is safe and can help control the cancer so a stem cell transplant may be possible.
Tehran, Tehran ProvinceAges 2–18 - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT04776330RecruitingPhase 1/Phase 2
BCMA-targeted CAR-T for relapsed or refractory multiple myeloma
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Kunming, YunnanAges 18–75 - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT04033302RecruitingPhase 1/Phase 2
Multi-CAR T cell therapy for CD7-positive blood cancers
This trial tests a new type of immune cell therapy (multi-CAR T cells) designed to target and kill cancer cells that have a marker called CD7. It may help people with certain blood cancers that have not responded well to other treatments.
Shenzhen, GuangdongAges 6 months–75 years - NCT04328298Recruiting
Register study of people in France eligible for CAR-T therapy
This study collects health data from people in France who received CAR-T treatment or are eligible to receive it. It helps doctors and researchers understand who can get CAR-T and how treatment is used in real life.
AmiensAges birth–99 years - NCT07193966RecruitingPhase 1/Phase 2
CAR-T cell therapy for advanced melanoma using NG2 and DLL3 targets
This trial tests a new treatment using your own immune cells (CAR-T cells) that are modified to find and attack melanoma cells with specific markers called NG2 and DLL3. It is for people whose melanoma has spread or come back after standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07127289RecruitingPhase 2
Stem cell infusion for low blood counts after CAR-T therapy
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07641023RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Lung Cancer
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT05370430RecruitingPhase 1
CAR T therapy targeting BAFF-R for certain NHL
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT06684639RecruitingEarly Phase 1
GD2-targeted CAR T cells for neuroblastoma
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
Chengdu, SichuanAges 1–18 - NCT05836896RecruitingPhase 1
Safety check of BCMA CAR T-cells made from your own immune cells
This early-phase trial tests whether a personalized BCMA-targeting CAR T-cell treatment is safe and what dose is tolerable in people whose lymphoma or myeloma has come back or did not respond to prior treatment. If you qualify, the team will monitor you closely for side effects to find the safest maximum tolerated dose.
DresdenAges 18 years+ - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07467863RecruitingPhase 1/Phase 2
Gene-modified immune cells for advanced lung cancer
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
Shenzhen, GuangdongAges 18–75
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car t cell?
- Yes. Clin2 currently lists 697 recruiting car t cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car t cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car t cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.